

May 20th, 12:30 PM

# Anti-pPKC $\theta$ (T538) Delivery via Cell Penetrating Peptide Mimics as a Novel Treatment of Aplastic Anemia

Emrah Ilker Ozay

*University of Massachusetts Amherst*

Gabriela Gonzalez-Perez


*University of Massachusetts Amherst*

Joe Torres

*University of Massachusetts Amherst*

*See next page for additional authors*

Follow this and additional works at: [http://escholarship.umassmed.edu/cts\\_retreat](http://escholarship.umassmed.edu/cts_retreat)

 Part of the [Cancer Biology Commons](#), [Cell Biology Commons](#), [Cellular and Molecular Physiology Commons](#), [Hemic and Lymphatic Diseases Commons](#), [Immunoprophylaxis and Therapy Commons](#), [Therapeutics Commons](#), and the [Translational Medical Research Commons](#)

---

Ozay, Emrah Ilker; Gonzalez-Perez, Gabriela; Torres, Joe; Tew, Gregory N.; and Minter, Lisa M., "Anti-pPKC $\theta$  (T538) Delivery via Cell Penetrating Peptide Mimics as a Novel Treatment of Aplastic Anemia" (2014). *UMass Center for Clinical and Translational Science Research Retreat*. 91.

[http://escholarship.umassmed.edu/cts\\_retreat/2014/posters/91](http://escholarship.umassmed.edu/cts_retreat/2014/posters/91)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

---

**Presenter Information**

Emrah Ilker Ozay, Gabriela Gonzalez-Perez, Joe Torres, Gregory N. Tew, and Lisa M. Minter

**Comments**

Abstract of poster presented at the 2014 UMass Center for Clinical and Translational Science Research Retreat, held on May 20, 2014 at the University of Massachusetts Medical School, Worcester, Mass.

**Creative Commons License**

This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](http://creativecommons.org/licenses/by-nc-sa/3.0/).

## **Anti-pPKC $\theta$ (T538) Delivery *via* Cell Penetrating Peptide Mimics as a Novel Treatment of Aplastic Anemia**

**Emrah Ilker Ozay<sup>1,2,3</sup>, Gabriela Gonzalez-Perez<sup>2</sup>, Joe Torres<sup>1,2</sup>, Gregory N. Tew<sup>1,2,3</sup>, and Lisa M. Minter<sup>1,2</sup>**

<sup>1</sup>Program in Molecular and Cellular Biology, <sup>2</sup>Department of Veterinary and Animal Sciences, <sup>3</sup>Department of Polymer Science and Engineering, University of Massachusetts, Amherst, MA, 01003

Contact information: eozay@mcb.umass.edu

The objective of this study is to deliver anti-pPKC $\theta$  (T538) into T cells (hPBMCs) by using cell penetrating peptide mimics (CPPMs) to neutralize PKC $\theta$  activity both *in vitro* and *in vivo*, with the eventual goal of treating aplastic anemia (AA). AA is an immune-mediated bone marrow failure disease caused by T helper type 1 (Th1) autoimmune responses, which destroy blood cell progenitors. It was previously reported that protein kinase C theta (PKC $\theta$ ), expressed specifically in T cells, plays an important role in T cell signaling by mediating Th1 differentiation. Mice treated with Rottlerin, a pharmacological inhibitor of PKC $\theta$ , are rescued from the disease when PKC $\theta$  phosphorylation was inhibited. Furthermore, humanized antibodies are increasingly gaining attention as therapies. The delivery of antibodies could be achieved *via* cell penetrating peptides (CPPs), which are able to internalize cargo into cells. Here, we designed, synthesized and characterized CPPMs to increase delivery efficiency of an antibody against phosphorylated PKC $\theta$  (T538), which subsequently interfered with the function of the kinase. We designed an *in vitro* delivery method for the CPPM/Anti-pPKC $\theta$  complex then assessed T cell activation and AA disease marker expression. Also, we generated an *in vivo* humanized mouse model of AA and tested the complex for delivery and effect on survival of these mice. Altogether the results reveal that PKC $\theta$  may be an optimal target for bone marrow failure treatment and intracellular antibody delivery may represent a novel approach for AA treatment.